Nimotuzumab is indicated for the treatment of various solid tumors, including head and neck cancer, glioma, colorectal cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma, and non-small cell lung cancer. It is approved in China for use in combination with radiotherapy for the treatment of stage III/IV nasopharyngeal carcinoma. Clinical studies have demonstrated that nimotuzumab enhances the efficacy of radiotherapy and chemoradiotherapy, improves disease control rates, and provides significant survival benefits, particularly in patients with unresectable locally advanced head and neck squamous cell carcinoma.